NIH NOTICES

Notice of Correction to Award Information in RFA-CA-19-038 "Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)" (NOT-CA-19-039)
National Cancer Institute

Notice of Correction to RFA-CA-19-007 "The Experimental Therapeutics Clinical Trials Network (UM1 Clinical Trial Required)" (NOT-CA-19-037)
National Cancer Institute

Notice of Intent to Publish: Funding Opportunity Announcement for Dissemination and Implementation Research in Health (R01 Clinical Trial Optional) (NOT-CA-19-038)
National Cancer Institute

Notice of a Pre-Application Webinar for RFA-CA-19-034, Feasibility and Planning Studies for Development of Specialized Programs of Research Excellence (SPORes) to Investigate Cancer Health Disparities (P20 Clinical Trial Optional) (NOT-CA-19-036)
National Cancer Institute

Notice of Correction to Eligibility Information in PAR-18-947 "Integrating Biospecimen Science Approaches into Clinical Assay Development (U01)" (NOT-CA-19-042)
National Cancer Institute

APRIL DEADLINES

Foundation and Other Sources

Department of Defense
Ovarian Cancer Research Program (OCRP) Investigator Initiated Research Award
Pre-Application Deadline: 4/23/2019
Full Application Deadline: 7/24/2019
https://www.grants.gov/web/grants/view-opportunity.html?oppId=313163
About: The OCRP Investigator-Initiated Research Award is intended to support high-impact research that has the potential to make an important contribution to ovarian cancer or patient/survivor care. Research projects may focus on any phase of research, from basic laboratory research through translational research, excluding clinical trials. The application must demonstrate logical reasoning and a sound scientific rationale established through a critical review and analysis of the literature for the application to be competitive. Applications must include preliminary data that are relevant to ovarian cancer and support the proposed research project.
Period of Support: Up to 3 years
Funds/Direct Costs: $450,000 direct costs for the entire period
Program Contact: CDMRP Help Desk
(301) 682-5507
help@eBRAP.org

Department of Defense
Ovarian Cancer Academy- Early Career Investigator Award
Pre-Application Deadline: 4/30/2019
Full Application Deadline: 7/31/2019
https://www.grants.gov/web/grants/view-opportunity.html?oppId=313160
About: The OCRP Ovarian Cancer Academy Award mechanism, which was initially created in FY09, is a unique, interactive virtual academy providing intensive mentoring, national networking, collaborations, and a peer group for junior faculty. The overarching goal of the Ovarian Cancer Academy (OCA) is to develop successful, highly productive ovarian cancer researchers in a collaborative research and career development environment.
Period of Support: Up to 4 years
Funds/Direct Costs: $725,000 direct costs for entire period
help@eBRAP.org
Tina's Wish for Ovarian Cancer Research
Tina's Wish Rising Star Grant
**Deadline:** 4/29/2019
[https://tinaswish.org/how-to-apply/](https://tinaswish.org/how-to-apply/)
**About:** The Honorable Tina Brozman Foundation (“Tina’s Wish”) is requesting Proposals for the Tina’s Wish Rising Star Grants for 2019. Tina’s Wish is committed to supporting early career researchers who bring fresh approaches to the study of the early detection or prevention of ovarian cancer. The goal is to assist and support promising researchers in the ovarian cancer field and to encourage them to take risks and develop innovative projects.

**Period of Support:** 2 years

**Funds/Direct Costs:** $75,000 total costs per year

**Program Contact:** Beverly Wolfer  
(212) 880-5757  
grants@tinaswish.org

Elsa U. Pardee Foundation
Cancer Research Grants
**Deadline:** 04/30/2019
[https://pardeefoundation.org/how-to-apply/](https://pardeefoundation.org/how-to-apply/)
**About:** The Elsa U. Pardee Foundation funds research to investigators in United States non-profit institutions proposing research directed toward identifying new treatments or cures for cancer. The Foundation particularly encourages grant applications for a one year period which will allow establishment of capabilities of new cancer researchers, or new cancer approaches by established cancer researchers. It is anticipated that this early stage funding by the Foundation may lead to subsequent and expanded support using government agency funding. Project relevance to cancer detection, treatment, or cure should be clearly identified.

**Period of Support:** 1 year

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Elsa U. Pardee Foundation  
(989) 832-3691

Multiple Institutes, including the National Cancer Institute
Time-Sensitive Obesity Policy and Program Evaluation (R01 Clinical Trial Not Allowed)
**Deadline:** 04/11/2019
**About:** This Funding Opportunity Announcement (FOA) establishes an accelerated review/award process to support time-sensitive research to evaluate a new policy or program that is likely to influence obesity related behaviors (e.g., dietary intake, physical activity, or sedentary behavior) and/or weight outcomes in an effort to prevent or reduce obesity.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** David Berrigan  
(240) 276-6752  
berrigand@mail.nih.gov

National Cancer Institute
Leveraging Cognitive Neuroscience to Improve Assessment of Cancer Treatment-Related Cognitive Impairment (R21 Clinical Trial Optional)
**Deadline:** 4/11/2019
**About:** This Funding Opportunity Announcement (FOA) encourages transdisciplinary research that will leverage cognitive neuroscience to improve traditional measurement of cognitive impairment following cancer treatment, often referred to as "chemobrain." A better understanding of the acute- and late-term cognitive changes following exposure...
to adjuvant chemotherapy and molecularly-targeted treatments, including hormonal therapy, for non-central nervous system tumors can inform clinical assessment protocols with downstream implications for survivorship care plans.

**Period of Support:** Up to 2 years  
**Funds/Direct Costs:** The combined budget for direct costs for the two-year project period may not exceed $275,000.  
**Program Contact:** Jerry Suls  
(240) 276-6811  
jerry.suls@nih.gov

---

**National Cancer Institute**  
**Predicting Behavioral Responses to Population-Level Cancer Control Strategies (R21)**  
**Deadline:** 4/11/2019  

**About:** The goal of this funding opportunity announcement (FOA) is to facilitate research to identify individual influences on the effectiveness of population-level strategies that target cancer-related behaviors. We seek to encourage collaborations among scientists with expertise in health policy research and implementation, as well as investigators in scientific disciplines that have not traditionally conducted cancer or policy research.  

**Period of Support:** Up to 2 years  
**Funds/Direct Costs:** $275,000 direct costs for entire period of support  
**Program Contact:** Rebecca Ferrer  
(240) 276-5075  
ferrerra@mail.nih.gov

---

**Request for Applications (RFA)**  
**Multiple Institutes, including the National Cancer Institute Advancing Cancer Immunotherapy by Mitigating Immune-related Adverse Events (irAEs) (U01 Clinical Trial Not Allowed)**  
**Deadline:** 4/25/2019  

**About:** The purpose of this FOA is to support improved cancer immunotherapy research projects that reduce the incidence and/or severity of immune-related adverse events (irAEs) while retaining anti-tumor efficacy. Single investigators and/or multidisciplinary teams with expertise in mechanisms of cancer immunology, immune tolerance, irAEs, autoimmunity, and/or patient characterization and selection are encouraged to propose projects that utilize appropriate model systems, clinical samples, and expertise of these research communities. The specific objectives are to generate new ideas and approaches to better understand and thereby reduce the incidence and/or severity of irAEs resulting from cancer immunotherapy.  

**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Each application budget is limited to $375,000 in direct costs (exclusive of F&A consortium costs) per year  
**Program Contact:** Crystal Wolfrey  
(240) 276-6277  
Crystal.wolfrey@nih.gov

---

**Intramural Funding Opportunities**  
**Massey Cancer Center**  
**Tina L. Bachas Oncology Nursing Clinical Practice Award**
**Deadline:** 4/30/2019  
[https://massey.vcu.edu/research/funding/tina-l-bachas-nursing-award/](https://massey.vcu.edu/research/funding/tina-l-bachas-nursing-award/)

**About:** Massey Cancer Center is pleased to announce the annual Tina L. Bachas Oncology Nursing Clinical Practice Project Award to advance oncology-nursing research and practice improvements. The intent of this award is to support nurses in oncology related endeavors, through evidence-based clinical practice projects in MCC. Projects should have a focus in oncology with a goal of improving the standard of care for patients.

**Period of Support:** 1 year  
**Funds/Direct Costs:** $5,000 for entire period  
**Internal Contact:** Olivia Patterson  
(804) 628-3400  
opatterson@vcu.edu

---

### MAY/JUNE DEADLINES

**Foundation and Other Sources**

**Alex’s Lemonade Stand Foundation (ALSF)**  

**'A' Awards**  
**Deadline:** 5/20/2019  
[https://www.alexislemonade.org/sites/default/files/2019_a-award_guidelines_final_0.pdf](https://www.alexislemonade.org/sites/default/files/2019_a-award_guidelines_final_0.pdf)

**About:** The 'A' Award is designed for the early independent career scientist who wants to establish a career in pediatric oncology research. The ideal candidate has an original project, can demonstrate outstanding career development support from the institution, and has a strong future commitment to pediatric cancer investigation. These awards are open to MD, MD/PhD and PhD applicants who are within 5 years of their first faculty appointment as an Assistant Professor. The 'A' Award offers up to $200,000 per year for four years, with the possibility of a fifth year of funding.

**Period of Support:** 4 years  
**Funds/Direct Costs:** Direct costs are limited to $200,000 per year  
**Program Contact:** Judy Oliver  
(610) 649-3034  
grants@alexislemonade.org

---

**Children’s Leukemia Research Association (CLRA)**  

**Research Grants**  
**Deadline:** 06/30/2019  
[https://www.childrensleukemia.org/research-grants-summary.asp](https://www.childrensleukemia.org/research-grants-summary.asp)

**About:** CLRA is on the leading edge of research, stimulating and facilitating the opportunity for new avenues of investigation. They fund research grants for doctors who are conducting the most promising research into leukemia, in the hopes of isolating the causes and finding a cure for this dreaded disease.

**Period of Support:** 1 year  
**Funds/Direct Costs:** $30,000 total costs for entire period of support  
**Program Contact:** CLRA  
(516) 222-1944  
info@childrensleukemia.org

---

**When Everyone Survives (WES) Leukemia Research Foundation**

**Request for Proposals in Leukemia Research**  
**Deadline:** 6/1/2019  
[https://www.wheneveryonesurvives.org/grant_application](https://www.wheneveryonesurvives.org/grant_application)

**About:** This request for proposals (RFP) is offered by the When Everyone Survives Foundation (WES Leukemia Research Foundation) to solicit innovative research in leukemia. Grants of $50,000 for one year are offered to new and established investigators who are requesting support for laboratory, translational, or clinical research related to acute leukemia. The WES Foundation is supports leukemia research because it recognizes that significant advances in the understanding, diagnosis, and treatment of leukemia are needed to achieve the goal of “When Everyone Survives”.

**Period of Support:** 1 year  
**Funds/Direct Costs:** $50,000 total costs for entire period of support  
**Program Contact:** WES Foundation  
(770) 595-3573  
contact@wheneveryonesurvives.org

---

**Lung Cancer Research Foundation**

**Pilot Grant Program**

**Deadline:** 6/14/2019  
[http://www.lungcancerresearchfoundation.org/research/funding-opportunities/lcrf-pilot-grant-program](http://www.lungcancerresearchfoundation.org/research/funding-opportunities/lcrf-pilot-grant-program)

**About:** The Lung Cancer Research Foundation’s annual pilot grant program provides funding for research focused on the prevention, diagnosis, treatment and cure of lung cancer. The goal of the program is to fund innovative projects across the spectrum of basic, translational, and clinical research.

**Period of Support:** 2 years  
**Funds/Direct Costs:** Direct costs are limited to $75,000 per year. No indirects allowed.  
**Program Contact:** LCRF office  
(212) 588-1580  
grants@lcrf.org

---

MCC Research Administration  
April 2019 Funding Newsletter  
Page 4 of 24
Alex's Lemonade Stand Foundation (ALSF)  
**Reach Grants**  
**Deadline:** 5/20/2019  
https://www.alexslemonade.org/sites/default/files/2019_reach_guidelines_final_0.pdf  
**About:** This award is designed to move hypothesis-driven research toward the clinic. A successful application will identify an unmet clinical need relevant to the care of patients with pediatric cancer and describe how the work performed will allow for the translation of hypothesis-driven research to the clinic, keeping broader clinical testing and implementation in view.  
**Period of Support:** 2 years  
**Funds/Direct Costs:** Direct costs are limited to $125,000 per year  
**Program Contact:** Brenda Delarm  
(866) 333-1213  
grants@alexslemonade.org

---

**National Cancer Institute**  
**Cancer Research Education Grants Program - Curriculum or Methods Development (R25)**  
**Deadline:** 05/25/2019  
**About:** The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. This FOA will support creative educational activities with a primary focus on Curriculum or Methods Development.  
**Period of Support:** Up to 2 years  
**Funds/Direct Costs:** $150,000 direct costs per year  
**Program Contact:** Jeannette Korczak  
(240) 276-5630  
korczakj@mail.nih.gov

---

**National Cancer Institute**  
**Cancer Research Education Grants Program - Courses for Skills Development (R25)**  
**Deadline:** 05/25/2019  
**About:** The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. This FOA will support creative educational activities with a primary focus on Courses for Skills Development.  
**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** $300,000 direct costs per year  
**Program Contact:** Jeannette Korczak  
(240) 276-5630  
korczakj@mail.nih.gov

---

**National Cancer Institute**  
**Cancer Research Education Grants Program - Research Experiences (R25)**  
**Deadline:** 05/25/2019  
**About:** The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. This FOA will support creative educational activities with a primary focus on Research Experiences.  
**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.  
**Program Contact:** Jennifer Isaacs  
(240) 276-6251  
jennifer.isaacs@nih.gov

---

*Program Announcements (PA)*

**National Cancer Institute**  
**Basic Research in Cancer Health Disparities (R21)**  
**Deadline:** 06/18/2019  
**About:** This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic research studies into the biological/genetic causes and mechanisms of cancer health disparities. These awards will support pilot and feasibility studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, (2) the development and testing of new methodologies and models, and (3) secondary data analyses.  
**Period of Support:** Up to 2 years  
**Funds/Direct Costs:** $275,000 direct costs for entire period of support  
**Program Contact:** Jennifer Isaacs  
(240) 276-6251  
jennifer.isaacs@nih.gov

---

**National Cancer Institute**  
**Basic Research in Cancer Health Disparities (R01)**  
**Deadline:** 06/18/2019  
**About:** This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities.  
**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.  
**Program Contact:** Jennifer Isaacs  
(240) 276-6251  
jennifer.isaacs@nih.gov
NIH. The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. This FOA will support creative educational activities with a primary focus on Research Experiences.

**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** $300,000 direct costs per year

**Program Contact:** Jeannette Korczak  
(240) 276-5630  
korczakj@mail.nih.gov

**Multiple Institutes, including the National Cancer Institute**

**Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (Parent T32)**  
**Deadline:** 05/25/2019  

**About:** The National Institutes of Health (NIH) will award Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grants (T32) to eligible, domestic institutions to enhance predoctoral and postdoctoral research training, including short-term research training, and help ensure that a diverse and highly trained workforce is available to meet the needs of the Nation’s biomedical, behavioral, and clinical research agenda.

**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Susan E. Lim  
(240) 276-5472  
lims@mail.nih.gov

**Multiple Institutes, including the National Cancer Institute**

**Neural Regulation of Cancer (R01)**  
**Deadline:** 06/27/2019  

**About:** This Funding Opportunity Announcement (FOA) encourages collaborative, transdisciplinary research with both neuroscience and cancer elements, which together will advance current understanding of the nervous system contribution to cancer.

**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Chamelli Jhappan  
(240) 276-6200  
jhappanc@mail.nih.gov

**National Cancer Institute**

**Cancer-Related Behavioral Research through Integrating Existing Data (R01)**  
**Deadline:** 06/07/2019  

**About:** This Funding Opportunity Announcement (FOA) invites applications that seek to integrate two or more independent data sets to answer novel cancer control and prevention questions. The goal is to encourage applications that incorporate Integrative Data Analysis (IDA) methods to study behavioral risk factors for cancer, including tobacco use, sedentary behavior, poor weight management, and lack of medical adherence to screening and vaccine uptake.

**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Richard P. Moser  
(240) 276-6915  
moserr@mail.nih.gov

**National Cancer Institute**

**Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21)**  
**Deadline:** 06/18/2019  

**About:** This Funding Opportunity Announcement (FOA) represents the continuation of an NCI program to enhance the diversity of the pool of the cancer research workforce by recruiting and supporting eligible junior investigators and Early Stage Investigators from groups that have been shown to be nationally underrepresented in the biomedical, behavioral, clinical and social sciences.

**Period of Support:** Up to 2 years  
**Funds/Direct Costs:** $275,000 direct costs for entire period of support

**Program Contact:** Abigail Soyombo  
(240) 276-6553  
abigail.soyombo@nih.gov

**National Cancer Institute**

**Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R01 Clinical Trial Optional)**  
**Deadline:** 6/5/2019  

**About:** This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider’s recommendation of the adolescent human papillomavirus (HPV) vaccine.

**Period of Support:** Up to 5 years
**Funds/Direct Costs:** Application budgets should reflect the actual needs of the proposed project.

**Program Contact:** Sarah Kobrin
(240) 276-6931
kobrins@mail.nih.gov

---

**Multiple Institutes, including the National Cancer Institute**
**Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)**

**Deadline:** 06/07/2019

**About:** This Funding Opportunity Announcement (FOA) will support pilot, feasibility or exploratory research in 5 priority areas in substance use epidemiology and health services, including: 1) responses to sudden and severe emerging drug issues 2) responses to emerging marijuana trends and topics related to the shifting policy landscape; 3) responses to unexpected and time-sensitive prescription drug abuse research opportunities 4) responses to unexpected and time-sensitive medical system issues; and 5) responses to unexpected and time-sensitive criminal or juvenile justice that relate to drug abuse and access and provision of health care service.

**Period of Support:** Up to 2 years

**Funds/Direct Costs:** Direct costs are limited to $275,000

**Program Contact:** Kelly D. Blake
(240) 281-5934
kelly.blake@nih.gov

---

**Multiple Institutes, including the National Cancer Institute**
**Biobehavioral Basis of Chronic Pain (R21 Clinical Trial Optional)**

**Deadline:** 06/16/2019

**About:** The purpose of the Funding Opportunity Announcement is to encourage grant applications from the scientific community on applying a biopsychosocial perspective to self-management of chronic pain.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Ann O'Mara
(240) 276-7050
omaraa@mail.nih.gov

---

**Multiple Institutes, including the National Cancer Institute**
**Applying a Biopsychosocial Perspective to Self-Management of Chronic Pain (R01)**

**Deadline:** 06/05/2019

**About:** The purpose of the Funding Opportunity announcement is to encourage grant applications from the scientific community on applying a biopsychosocial perspective to self-management of chronic pain.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Ann O'Mara
(240) 276-7050
omaraa@mail.nih.gov

---

**Multiple Institutes, including the National Cancer Institute**
**Increasing Uptake of Evidence-Based Screening in Diverse Adult Populations**

**Deadline:** 06/05/2019

**About:** This Funding Opportunity Announcement (FOA) invites applications that seek to understand strategies to reduce disparities in the uptake of evidence-based screening (e.g. screening recommendations proven to be effective based on rigorous systematic review of scientific evidence by authoritative committees) across the adult lifespan.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Erica Breslau
(240) 276-6773
breslaue@mail.nih.gov
National Cancer Institute
Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R21)
Deadline: 06/16/2019
About: This Funding Opportunity Announcement (FOA) encourages transdisciplinary and translational research that will identify the specific biological or biobehavioral pathways through which physical activity and/or weight control (either weight loss or avoidance of weight gain) may affect cancer prognosis and survival. Research applications should test the effects of physical activity, alone or in combination with weight control (either weight loss or avoidance of weight gain), on biomarkers of cancer prognosis among cancer survivors identified by previous animal or observational research on established biomarkers other than insulin/glucose metabolism, especially those obtained from tumor tissue sourced from repeat biopsies where available.
Period of Support: 2 years
Funds/Direct Costs: $275,000 direct costs for entire period of support
Program Contact: Frank Perna
(240) 276-6782
pernafm@mail.nih.gov

National Cancer Institute
Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01)
Deadline: 06/05/2019
About: Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) seeks research project (R01) grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance.
Period of Support: Up to 5 years
Funds/Direct Costs: $499,999 direct costs per year
Program Contact: Anne Menkens
(240) 276-6510
menkensa@mail.nih.gov

Multiple Institutes, including the National Cancer Institute
Advancing Translational and Clinical Probiotic/Prebiotic and Human Microbiome Research (R01)
Deadline: 06/05/2019
About: The purpose of this funding opportunity announcement (FOA) is twofold: 1). to accelerate translational and clinical Phase I and II a/b safety and efficacy studies for substantiating measurable functional benefits of probiotic/prebiotic components and/or their combinations; and; 2). to understand the underlying mechanisms of their action(s), and variability in responses to these interventions.
Period of Support: Up to 5 years
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Program Contact: Gabriela Riscuta
(240) 276-7118
gabriela.riscuta@nih.gov

National Cancer Institute
Early-life Factors and Cancer Development Later in Life (R03)
Deadline: 06/16/2019
About: The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research focused on the role of early-life factors (maternal-paternal, in utero, birth and infancy, puberty, adolescence, and young adult years) in cancer development later in life.
Period of Support: Up to 2 years
Funds/Direct Costs: $100,000 direct costs per year
Program Contact: Somdat Mahabir
(240) 276-6941
mahabir@mail.nih.gov

National Cancer Institute
Early-life Factors and Cancer Development Later in Life (R01)
Deadline: 06/05/2019
About: The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research focused on the role of early-life factors (maternal-paternal, in utero, birth and infancy, puberty, adolescence, and young adult years) in cancer development later in life.
Period of Support: Up to 5 years
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Program Contact: Somdat Mahabir
(240) 276-6941
mahabir@mail.nih.gov

Multiple Institutes, including the National Cancer Institute
Reducing Overscreening for Breast, Cervical, and Colorectal Cancers among Older Adults (R01)
Deadline: 06/05/2019  

About: The purpose of this Funding Opportunity Announcement (FOA) is to promote research on interventions, based in healthcare settings, designed to reduce overscreening for breast, cervical, or colorectal cancers among average-risk older adults.

Period of Support: Up to 5 years  
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.

Program Contact: Erica Breslau  
(240) 276-6773  
breslaue@mail.nih.gov

National Cancer Institute  
The Interplay of Cell Death Pathways in Cancer Cell Survival and Resistance to Therapy (R21)  
Deadline: 06/16/2019  

About: The purpose of this funding opportunity announcement (FOA) is to stimulate research in the interplay between cell death pathways in naïve and drug resistant cancers.

Period of Support: Up to 2 years  
Funds/Direct Costs: $275,000 direct costs for entire period of support

Program Contact: Konstantin Salnikow  
(240) 276-6230  
salnikok@mail.nih.gov

National Cancer Institute  
Discovery of Small Molecule Immunomodulators for Cancer Therapy (R01)  
Deadline: 06/05/2019  

About: The purpose of this funding opportunity announcement (FOA) is to promote the discovery of novel small molecules that may enhance the ability of the immune system to selectively recognize and attack cancer cells. This FOA encourages the design of research projects that utilize the following phases of discovery research: 1) assay development specifically designed for immunoncology targets with the intent to screen for novel small molecule compounds that show potential as either probes or drugs, or as pre-therapeutic leads; 2) screen implementation for immunomodulatory targets to identify initial screening hits; 3) hit validation through secondary orthogonal and counter screening assays, and hits prioritization; and 4) hit-to-lead optimization.

Period of Support: Up to 4 years  
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.

Program Contact: Sundar Venkatachalam  
(240) 276-7304  
sundarv@nih.gov

National Cancer Institute  
Leveraging Population-based Cancer Registry Data to Study Health Disparities (R01)  
Deadline: 06/05/2019  

About: The goal of this Funding Opportunity Announcement (FOA) is to efficiently use the existing cancer registry infrastructure by augmenting data already collected with additional information needed to understand health disparities among people diagnosed with cancer. Specifically, this FOA will support the study of factors influencing observed health disparities within the framework of population-based cancer registries by the inclusion of data not routinely collected by or linked to the registries.

Period of Support: Up to 5 years  
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.

Program Contact: Kathleen Cronin  
(240) 276-6836  
cronink@mail.nih.gov

Multiple Institutes, including the National Cancer Institute  
Research Project Grant (Parent R01)  
Deadline: 06/05/2019  

About: The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

Period of Support: Up to 5 years  
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.

Program Contact: Crystal Wolfrey  
(240) 276-6277  
wolfreyc@mail.nih.gov

National Cancer Institute  
Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R01 Clinical Trial Optional)  
Deadline: 06/05/2019  
This Funding Opportunity Announcement (FOA) encourages transdisciplinary and translational research that will identify the specific biological or biobehavioral pathways through which physical activity and/or weight control (either weight loss or avoidance of weight gain) may affect cancer prognosis and survival. Research applications should test the effects of physical activity, alone or in combination with weight control (either weight loss or avoidance of weight gain), on biomarkers of cancer prognosis among cancer survivors identified by previous animal or observational research on established biomarkers other than insulin/glucose metabolism, especially those obtained from tumor tissue sourced from repeat biopsies where available.

**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Frank Perna  
(240) 276-6782  
pernafm@mail.nih.gov

---

**National Cancer Institute**  
**Traceback Testing: Increasing Identification and Genetic Counseling of Mutation Carriers through Family-based Outreach (U01 Clinical Trial Optional)**  
**Deadline:** 6/5/2019  

**About:** The purpose of the Funding Opportunity Announcement (FOA) is to support pilot research projects using a "Traceback" approach to genetic testing women with a personal or family history of ovarian cancer and reaching out to family members to identify unaffected individuals at increased risk for cancer in different clinical contexts and communities, including racially/ethnically diverse populations.

**Period of Support:** Up to 4 years  
**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Goli Samimi  
(301) 276-6582  
golisamimi@nih.gov

---

**National Cancer Institute**  
**NCI Transition Career Development Award to Promote Diversity (K22 No Independent Clinical Trials)**  
**Deadline:** 06/12/2019  

**About:** The purpose of the NCI Transition Career Development Award to Promote Diversity is to assist postdoctoral fellows or individuals in equivalent positions to transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist.

**Period of Support:** Up to 3 years  
**Funds/Direct Costs:** Award budgets are composed of salary and other program-related expenses, as described in announcement.

**Program Contact:** Abigail Soyombo  
(240) 276-6553  
Abigail.Soyombo@nih.gov

---

**National Cancer Institute**  
**Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 - Clinical Trial Not Allowed)**  
**Deadline** 06/05/2019  

**About:** The purpose of this Funding Opportunity Announcement (FOA) is to promote epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the United States.

**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Tram Kim Lam  
(240) 276-6967  
Tram.Lam@nih.gov

---

**National Cancer Institute**  
**Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery (R21 Clinical Trial Optional)**  
**Deadline:** 06/16/2019  

**About:** The purpose of this funding opportunity announcement (FOA) is to encourage exploratory/developmental research grant applications to: (1) assess and describe the current state of oral anticancer medication utilization, delivery, and adherence; (2) identify structural, systemic, and psychosocial barriers to adherence; and (3) develop models and strategies to improve safe and effective delivery of these agents so that clinical outcomes are optimized.

**Period of Support:** Up to 2 years  
**Funds/Direct Costs:** The combined budget for direct costs for the two-year project period may not exceed $275,000.

**Program Contact:** Wendy Nelson  
(240) 276-6971  
nelsonw@mail.nih.gov

---

MCC Research Administration  
April 2019 Funding Newsletter  
Page 10 of 24
Multiple Institutes, including the National Cancer Institute

**Advancing the Science of Geriatric Palliative Care (R21 - Clinical Trial Optional)**

**Deadline:** 06/16/2019  

**About:** This Funding Opportunity Announcement (FOA) encourages exploratory or developmental research grant applications to develop new tools, methods, and models focused on palliative care in geriatric populations. This FOA covers studies in a variety of settings including hospitals (and specific sites within hospitals including specialty medical or surgical wards, intensive care units, and emergency departments), post-acute care settings, outpatient clinics and doctors’ offices, patients’ homes and other residential settings, assisted living facilities, nursing homes, hospices, and other healthcare or community settings.

**Period of Support:** Up to 2 years  
**Funds/Direct Costs:** The combined budget for direct costs for the two-year project period may not exceed $275,000.  
**Program Contact:** Wen-Ying Sylvia Chou  
(240) 276-6954  
chouws@mail.nih.gov

---

Multiple Institutes, including the National Cancer Institute

**End-of-Life and Palliative Care Health Literacy: Improving Outcomes in Serious, Advanced Illness (R01 Clinical Trial Optional)**

**Deadline:** 06/05/2019  

**About:** This funding opportunity announcement (FOA) seeks to stimulate research focused on identification of the key barriers to effective end-of-life and palliative care (EOLPC) health literacy in diverse settings and populations, and to create novel strategies, interventions, and models of care to improve EOLPC health literacy, with the goal of improving outcomes for individuals with serious, advanced illness and their families and caregivers.

**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.  
**Program Contact:** Erica S. Breslau  
(240) 276-6773  
breslaue@mail.nih.gov

---

National Cancer Institute

**Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R21)**

**Deadline:** 06/16/2019  

**About:** This Funding Opportunity Announcement (FOA) encourages collaborative applications that will contribute to the identification and characterization of patients at risk of developing cancer treatment-related cardiotoxicity. The primary intent is to mitigate cardiovascular dysfunction while optimizing cancer outcomes.

**Period of Support:** Up to 2 years  
**Funds/Direct Costs:** The combined budget for direct costs for the entire project period may not exceed $275,000.  
**Program Contact:** Nonniekaye Shelburne  
(240) 276-6897  
nshelburne@mail.nih.gov

---

Multiple Institutes, including the National Cancer Institute

**Multilevel Interventions in Cancer Care Delivery: Follow-up to Abnormal Screening Tests (R01 Clinical Trial Optional)**

**Deadline:** 06/05/2019  

**About:** This Funding Opportunity Announcement (FOA) encourages applications that develop and test multilevel interventions to improve follow-up to abnormal screening tests for breast, cervical, colorectal, or lung cancers. Improving follow-up to abnormal screening tests is dependent on factors at the patient, provider, clinical team, clinic, healthcare institution, or community setting levels. Appropriate applications for this FOA should propose to intervene at two or more levels, and measure outcomes at three or more levels, while accounting for interactions that occur between and across levels.

**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.  
**Program Contact:** Erica S. Breslau  
(240) 276-6773  
breslaue@mail.nih.gov
caregivers.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Lynn Adams  
(301) 594-8911  
lynn.adams@nih.gov

---

**National Cancer Institute**  
**Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)**  
**Deadline:** 06/16/2019  

**About:** The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of Exploratory/Developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.

**Period of Support:** Up to 2 years

**Funds/Direct Costs:** The combined budget for direct costs for the two-year project period may not exceed $275,000.

**Program Contact:** Miguel R. Ossandon  
(240) 276-5714  
ossandom@mail.nih.gov

---

**National Cancer Institute**  
**Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional)**  
**Deadline:** 06/05/2019  

**About:** This Funding Opportunity Announcement (FOA) will support the development and characterization of state-of-the-art biomimetic tissue-engineered technologies for cancer research. Collaborative, multidisciplinary projects that engage the fields of regenerative medicine, tissue engineering, biomaterials, and bioengineering with cancer biology will be essential for generating novel experimental models that mimic cancer pathophysiology in the context of a testable cancer research hypothesis. The projects supported by this FOA will collectively participate in the Cancer Tissue Engineering Collaborative (TEC) Research Program.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are limited to $400,000 Direct Costs per year.

**Program Contact:** Nastaran Zahir  
(240) 276-7610

---

**Multiple Institutes, including the National Cancer Institute**  
**Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R21-Clinical Trial Not Allowed)**  
**Deadline:** 06/16/2019  

**About:** This FOA will support activities proposing to conduct analyses of existing ABCD Study data to accelerate the pace of research on child health and development, including: cross-sectional and/or longitudinal analyses; development of new or advanced statistical methods; and/or integration of multiple data sets with common data elements. Existing data provide unique opportunities to answer novel research questions in a cost-effective way. We also strongly encourage inclusion of statisticians, computational neuroscientists, and interdisciplinary teams to address novel research questions using these data.

**Period of Support:** Up to 2 years

**Funds/Direct Costs:** The combined budget for direct costs for the two-year project period may not exceed $275,000.

**Program Contact:** Crystal Wolfrey  
(240) 276-6277  
wolfreyc@mail.nih.gov

---

**Multiple Institutes, including the National Cancer Institute**  
**Bioengineering Research Grants (BRG) (R01 Clinical Trial Required)**  
**Deadline:** 06/05/2019  

**About:** The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Houston Baker  
(240) 276-5908  
bakerhou@mail.nih.gov

---

**Multiple Institutes, including the National Cancer Institute**  
**Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Not Allowed)**
Deadline: 06/12/2019

About: The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation.

Period of Support: Up to 5 years

Funds/Direct Costs: Award budgets are composed of salary and other program-related expenses, as described in announcement.

Program Contact: Susan Lim
(240) 276-5588
lims@mail.nih.gov

National Cancer Institute
National Cancer Institute’s Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
Deadline: 06/05/2019

About: The purpose of this Funding Opportunity Announcement (FOA) is to seek research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of the National Cancer Institute’s (NCI) Division of Cancer Treatment and Diagnosis (DCTD).

Period of Support: Up to 5 years

Funds/Direct Costs: Application budgets are limited to less than $500,000 in direct costs per year.

Program Contact: Lori A. Henderson
(240) 276-5930
hendersonlori@mail.nih.gov

National Cancer Institute
Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
Deadline: 06/05/2019

About: Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for support of investigator-initiated clinical trials that have the potential to reduce the burden of cancer through improvements in early detection, prevention, health care delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health.

Period of Support: Up to 5 years

Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.

Program Contact: Brandy Heckman-Stoddard
(240) 276-7048
heckmanbm@mail.nih.gov

Multiple Institutes, including the National Cancer Institute Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)
Deadline: 06/05/2019

About: The purpose of this Funding Opportunity Announcement (FOA) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease.

Period of Support: Up to 5 years

Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.

Program Contact: Miguel R. Ossandon
(240) 276-5714
ossandom@mail.nih.gov

National Cancer Institute
NCI Small Grants Program for Cancer Research (NCI Omnibus R03 Clinical Trial Optional)
Deadline: 06/28/2019

About: This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

Period of Support: Up to 2 years

Funds/Direct Costs: A budget for direct costs of up to $50,000 per year may be requested.

Program Contact: Crystal Wolfrey
(240) 276-6277
wolfreyc@mail.nih.gov

National Cancer Institute
Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R01 Clinical Trial Required)
Deadline: 06/28/2019

About: This Funding Opportunity Announcement (FOA) is
intended to support clinical trials conducting preliminary evaluation of the safety and efficacy of imaging agents, as well as an assessment of imaging systems, image processing, image-guided planning and/or execution therapy, contrast kinetic modeling, 3-D reconstruction and other quantitative tools.

**Period of Support:** Up to 3 years

**Funds/Direct Costs:** Application budgets are limited to $500,000 in direct costs per year.

**Program Contact:** Lori A. Henderson  
(240) 276-5930  
hendersonlori@mail.nih.gov

---

**Multiple Institutes, including the National Cancer Institute**

**Age-related Microbiota Changes and their Implications in Chronic Disease Prevention, Treatment and Progression (R21 Clinical Trial Optional)**

**Deadline:** 06/16/2019  

**About:** The overall purpose of this funding opportunity announcement (FOA) is to assess the role of the microbiome in health and disease during aging. This initiative will support research projects designed to evaluate changes in the microbiota during lifetime and its influence in health and disease status in the elderly, including those from racial/ethnic minority and underserved populations and understand the underlying mechanisms of microbiota interactions in aged subjects as relate to health and disease.

**Period of Support:** Up to 2 years

**Funds/Direct Costs:** The combined budget for direct costs for the two-year project period may not exceed $275,000.

**Program Contact:** Kaye Miles  
(301) 827-4886  
kaye.miles@nih.gov

---

**National Cancer Institute**

**Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)**

**Deadline:** 06/05/2019  

**About:** Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) seeks research project (R01) grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are limited to $499,999 (maximum) in direct costs per year

**Program Contact:** Anne Menkens  
(240) 276-6510  
menkensa@mail.nih.gov

---

**Multiple Institutes, including the National Cancer Institute**

**Reducing Overscreening for Breast, Cervical, and Colorectal Cancers among Older Adults (R21 Clinical Trial Optional)**

**Deadline:** 06/16/2019  

**About:** The purpose of this Funding Opportunity Announcement (FOA) is to: identify new, information technology (IT)-enabled delivery models that support systematic screening and treatment of depression in cancer patients; test the feasibility of implementing these new delivery models in a variety of oncology practice settings, especially those serving under-served populations; test the effectiveness of these new delivery models, and their components, in a variety of oncology practice settings, especially those serving under-served populations; and evaluate the sustainability and scalability of these new delivery models.

**Period of Support:** Up to 2 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Gurvaneet S. Randhawa  
(240) 276-6940  
gurvaneet.randhawa@nih.gov

---

**Multiple Institutes, including the National Cancer Institute**

**Using Information Technology to Support Systematic Screening and Treatment of Depression in Oncology Practices (R01 Clinical Trial Optional)**

**Deadline:** 06/05/2019  

**About:** The purpose of this Funding Opportunity Announcement (FOA) is to: identify new, information technology (IT)-enabled delivery models that support systematic screening and treatment of depression in cancer patients; test the feasibility of implementing these new delivery models in a variety of oncology practice settings, especially those serving under-served populations; test the effectiveness of these new delivery models, and their components, in a variety of oncology practice settings, especially those serving under-served populations; and evaluate the sustainability and scalability of these new delivery models.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Kaye Miles  
(301) 827-4886  
kaye.miles@nih.gov

---

**National Cancer Institute**

**Diet and Physical Activity Assessment Methodology (R21 Clinical Trial Not Allowed)**

**Deadline:** 06/05/2019  

**About:** Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) seeks research project (R01) grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are limited to $499,999 (maximum) in direct costs per year

**Program Contact:** Anne Menkens  
(240) 276-6510  
menkensa@mail.nih.gov

---

**Multiple Institutes, including the National Cancer Institute**

**Diet and Physical Activity Assessment Methodology (R21 Clinical Trial Not Allowed)**

**Deadline:** 06/05/2019  

**About:** Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) seeks research project (R01) grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are limited to $499,999 (maximum) in direct costs per year

**Program Contact:** Anne Menkens  
(240) 276-6510  
menkensa@mail.nih.gov
**National Cancer Institute**

**Leveraging Population-based Cancer Registry Data to Study Health Disparities (R21)**

*Deadline: 06/16/2019*


*About:* The goal of this Funding Opportunity Announcement (FOA) is to efficiently use the existing cancer registry infrastructure by augmenting data already collected with additional information needed to understand health disparities among people diagnosed with cancer.

*Period of Support:* Up to 2 years

*Funds/Direct Costs:* The combined budget for direct costs for the two-year project period may not exceed $275,000.

*Program Contact:* Kathleen Cronin  
(240) 276-6836  
cronink@mail.nih.gov

**National Cancer Institute**

**Integration of Individual Residential Histories into Cancer Research (R01)**

*Deadline: 06/05/2019*


*About:* The purpose of this Funding Opportunity Announcement (FOA) is to support substantive investigation of the role of individual residential histories in cancer etiology and outcomes, and to encourage the development of complex analytical strategies in support of substantive investigation.

*Period of Support:* Up to 5 years

*Funds/Direct Costs:* Application budgets are not limited but need to reflect the actual needs of the proposed project.

*Program Contact:* Zaria Tatalovich  
(240) 276-6976  
tatalovichzp@mail.nih.gov

**Multiple Institutes, including the National Cancer Institute**

**Exploratory/Developmental Clinical Research Grants in Obesity (R21 Clinical Trial Optional)**

*Deadline: 06/16/2019*


*About:* This Funding Opportunity Announcement (FOA) encourages research grant applications from institutions/organizations that propose to conduct exploratory/developmental clinical studies that will accelerate the development of effective interventions for prevention or treatment of overweight or obesity in adults and/or children.

*Period of Support:* Up to 2 years

*Funds/Direct Costs:* Application budgets are limited to $275,000 in direct costs per year.

*Program Contact:* Tanya Agurs-Collins  
(240) 276-6956  
collinsta@mail.nih.gov
Multiple Institutes, including the National Cancer Institute
Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health (R01 Clinical Trial Optional)
Deadline: 06/05/2019
About: This FOA calls for research grant applications that address patient adherence to treatment and prevention regimens to promote health outcomes. Applications may address healthcare regimen initiation, implementation, and/or persistence by patients.
Period of Support: Up to 5 years
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Program Contact: Wendy Nelson
(240) 276-6971
nelsonw@mail.nih.gov

Multiple Institutes, including the National Cancer Institute
Assay development and screening for discovery of chemical probes or therapeutic agents (R01)
Deadline: 06/05/2019
About: Through this funding opportunity announcement (FOA), NIH wishes to stimulate research in discovery and development of novel, small molecules for their potential use in studying disease treatment relevant to the missions of the participating NIH Institutes; and to generate new insight into the biology of relevant diseases and processes that have yet to be validated as important drug targets.
Period of Support: Up to 4 years
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Program Contact: Suzanne Forry
(240) 276-5922
forryscs@mail.nih.gov

Multiple Institutes, including the National Cancer Institute
Biology of Lung, and Head and Neck Preneoplasias (R21 - Clinical Trial Not Allowed)
Deadline: 06/15/2019
About: This Funding Opportunity Announcement (FOA) seeks applications investigating mechanistic and biological aspects of preneoplasia leading to lung, and head and neck (HN) cancers. Despite improved therapies and a deeper molecular understanding of lung and HN cancers, these tumors remain a major health problem in the United States and globally.
Period of Support: Up to 2 years
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Program Contact: Young S. Kim
(240) 276-7115
yk47s@nih.gov

Multiple Institutes, including the National Cancer Institute
Academic-Industrial Partnerships to Translate and Validate in vivo Cancer Imaging Systems (R01 Clinical Trial Optional)
Deadline: 06/05/2019
About: The purpose of this Funding Opportunity Announcement (FOA) is to stimulate translation of scientific discoveries and engineering developments in imaging or spectroscopic technologies into methods or tools that address problems in cancer biology, risk of cancer development, diagnosis, treatment, and/or disease status.
Period of Support: Up to 5 years
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Program Contact: Houston Baker
(240) 276-5908
bakerhou@mail.nih.gov

Multiple Institutes, including the National Cancer Institute
Modulating Intestinal Microbiota to Enhance Protective Immune Responses against Cancer (R01 Clinical Trial Not Allowed)
Deadline: 06/10/2019
About: The purpose of this Funding Opportunity Announcement (FOA) is to support research which can elucidate mechanism(s) of action by which gut microbes inhibit or enhance anti-tumor immune responses. Thus, research projects should be focused on delineating how specific microbes or their metabolites target host immune responses to prevent colitis-associated or sporadic tumor formation.
Period of Support: Up to 5 years
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Program Contact: Young S. Kim
(240) 276-7115
yk47s@nih.gov

Multiple Institutes, including the National Cancer Institute
Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)
Deadline: 06/16/2019

April 2019 Funding Newsletter
Page 16 of 24
About: The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.

**Period of Support:** Up to 2 years
**Funds/Direct Costs:** Application budgets are limited to $275,000 in direct costs per year
**Program Contact:** Miguel R. Ossandon
(240) 276-5714
ossandom@mail.nih.gov

Multiple Institutes, including the National Cancer Institute
Perception and Cognition Research to Inform Cancer Image Interpretation (R01)
**Deadline:** 05/30/2019

About: The purpose of this Funding Opportunity Announcement (FOA) is to facilitate research on the perceptual and cognitive processes underlying the performance of cancer image observers in radiology and pathology, in order to improve the accuracy of cancer detection and diagnosis.

**Period of Support:** Up to 5 years
**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.
**Program Contact:** Todd Horowitz
(240) 276-6963
todd.horowitz@nih.gov

National Cancer Institute
Biology of Bladder Cancer (R01 Clinical Trial Optional)
**Deadline:** 06/05/2019

About: This Funding Opportunity Announcement (FOA) encourages applications investigating the biology and underlying mechanisms of bladder cancer. Applications that involve multidisciplinary teams and use clinical specimens or investigate both normal and cancer processes are encouraged.

**Period of Support:** Up to 5 years
**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.
**Program Contact:** Ron Johnson
(240) 276-6250
rjohnso2@mail.nih.gov

National Cancer Institute
Quantitative Imaging Tools and Methods for Cancer Response Assessment (U01)
**Deadline:** 05/09/2019

About: This purpose of this Funding Opportunity Announcement (FOA) is to provide a mechanism of support to research organizations interested in clinically translating already optimized quantitative imaging software tools capable of measuring or predicting the response of cancer to clinical therapies, or in translating imaging tools for planning and validating radiation therapy treatment strategies in clinical trials.

**Period of Support:** Up to 5 years
**Funds/Direct Costs:** Application budgets are limited to $500,000 in direct costs per year
**Program Contact:** Robert J. Nordstrom
(240) 276-5934
nordstrr@mail.nih.gov

Multiple Institutes, including the National Cancer Institute
Testing Interventions for Health-Enhancing Physical Activity (R01 - Clinical Trial Optional)
**Deadline:** 06/05/2019

About: The purpose of this Funding Opportunity Announcement (FOA) is to fund highly innovative and promising research that tests multi-level physical activity intervention programs acting on at least two levels of the socio-ecological model and designed to increase health-enhancing physical activity: 1) in persons or groups that can benefit from such activity; and 2) that could be made scalable and sustainable for broad use across the nation.

**Period of Support:** Up to 5 years

MCC Research Administration
April 2019 Funding Newsletter
**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Frank Perna
(240) 276-6782
pernafm@mail.nih.gov

---

**National Cancer Institute**

**National Cancer Institute Program Project Applications (P01 Clinical Trial Optional)**

**Deadline:** 05/25/2019

**About:** With this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for investigator-initiated Program Project (P01) applications. The proposed Program may address any of the broad areas of cancer research, including (but not limited to) cancer biology, cancer prevention, cancer diagnosis, cancer treatment, and cancer control.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Referral Officer
(240) 276-6390
ncirefof@dea.nci.nih.gov

---

**Multiple Institutes, including the National Cancer Institute**

**Improving Smoking Cessation in Socioeconomically Disadvantaged Populations via Scalable Interventions (R01 Clinical Trial Optional)**

**Deadline:** 06/13/2019

**About:** The purpose of this Funding Opportunity Announcement (FOA) is to provide support for highly innovative and promising intervention research designed to improve smoking cessation outcomes among socioeconomically disadvantaged populations.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Yvonne Hunt
(240) 276-6975
huntym@mail.nih.gov

---

**National Cancer Institute**

**Innovative Research in Cancer Nanotechnology (IRCN)**

**Deadline:** 05/23/2019

**About:** This Funding Opportunity Announcement (FOA) encourages applications for the development of innovative research projects in cancer nanotechnology. This initiative, to be known as Innovative Research in Cancer Nanotechnology (IRCN), is a component of a broader program that is the NCI Alliance for Nanotechnology in Cancer.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are limited to $450K in direct costs per year

**Program Contact:** Christopher Hartshorn
(240) 781-3315
christopher.hartshorn@nih.gov

---

**National Cancer Institute**

**Modulating Intestinal Microbiota to Enhance Protective Immune Responses against Cancer (R21 Clinical Trial Not Allowed)**

**Deadline:** 06/10/2019

**About:** The purpose of this Funding Opportunity Announcement (FOA) is to support research which can elucidate mechanism(s) of action by which gut microbes inhibit or enhance anti-tumor immune responses. Thus, research projects should be focused on delineating how specific microbes or their metabolites target host immune responses to prevent colitis-associated or sporadic tumor formation.

**Period of Support:** Up to 2 years

**Funds/Direct Costs:** The combined budget for direct costs for the two-year project period may not exceed $275,000.

**Program Contact:** Young S. Kim
(240) 276-7115
yk47s@nih.gov

---

**National Cancer Institute**

**Perception and Cognition Research to Inform Cancer Image Interpretation (R21)**

**Deadline:** 05/30/2019

**About:** The purpose of this Funding Opportunity Announcement (FOA) is to facilitate research on the perceptual and cognitive processes underlying the performance of cancer image observers in radiology and pathology, in order to improve the accuracy of cancer detection and diagnosis.

**Period of Support:** Up to 2 years

**Funds/Direct Costs:** $275,000 direct costs for entire period of support

**Program Contact:** Todd Horowitz
(240) 276-6963
todd.horowitz@nih.gov
National Cancer Institute
Microbial-based Cancer Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed)
Deadline: 06/05/2019
About: The overall purpose of this funding opportunity announcement (FOA) is to stimulate the development of novel microbial-based cancer therapies, especially for conditions where conventional cancer therapies are inadequate, such as poorly vascularized, hypoxic, solid tumors, dormant or slowly dividing cells resistant to current interventions, and brain tumors. Utilizing bacteria, archaeabacteria, bacteriophages and other non-virus microorganisms, this initiative will support research projects designed to study the underlying mechanisms of the complex interactions between microorganisms, tumor, and immune system.
Period of Support: Up to 5 years
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Program Contact: Avi Rasooly
(240) 276-6196
rasoolya@mail.nih.gov

National Cancer Institute
Oncology Co-Clinical Imaging Research Resources to Encourage Consensus on Quantitative Imaging Methods and Precision Medicine (U24 - Clinical Trial Optional)
Deadline: 06/14/2019
About: The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement applications to develop research resources that will encourage a consensus on how Quantitative Imaging (QI) methods are optimized to improve the quality of imaging results for co-clinical trials.
Period of Support: Up to 5 years
Funds/Direct Costs: Application budgets for direct costs up to $500,000 per year may be requested.
Program Contact: Nancy Boudreau
(240) 276-6702
nancy.boudreau@nih.gov

Multiple Institutes, including the National Cancer Institute
The Role of Epitranscriptomics in Development and Disease (R01 - Clinical Trial Not Allowed)
Deadline: 06/03/2019
About: The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from the scientific community to support outstanding research in the area of epitranscriptomics, i.e., the chemical modifications of RNA.
Period of Support: Up to 5 years
Funds/Direct Costs: Application budgets should not exceed $499,999 direct costs per year.
Program Contact: Jennifer Strasburger
(240) 276-6230
strasbuj@mail.nih.gov

Multiple Institutes, including the National Cancer Institute
Precision Imaging of Oral Lesions (R01- Clinical Trial Not Allowed)
Deadline: 06/05/2019
About: The intent of this Funding Opportunity Announcement (FOA) is to advance the development, adaptation, optimization, and validation of accurate, reproducible, specific, and sensitive imaging approaches to improve diagnosis, treatment, and treatment monitoring for diseases and conditions in the oral cavity and oropharynx.
Period of Support: Up to 5 years
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Program Contact: Shane Woodward
(240) 276-6303
woodwars@mail.nih.gov

National Cancer Institute
Microbial-based Cancer Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed)
Deadline: 06/16/2019
About: The overall purpose of this funding opportunity announcement (FOA) is to stimulate exploratory development of novel microbial-based cancer therapies, especially for conditions where conventional cancer therapies are inadequate, such as poorly vascularized, hypoxic, solid tumors, dormant or slowly dividing cells resistant to current interventions, and brain tumors. The FOA also aims to support research into the use of microorganisms for cancer treatment and to complement or synergize with current therapies.
Period of Support: Up to 2 years
Funds/Direct Costs: Application budgets are limited to $275,000 per year.
Program Contact: Avi Rasooly
(240) 276-6196
rasoolya@mail.nih.gov
National Cancer Institute
U.S. Tobacco Control Policies to Reduce Health Disparities (R21)
Deadline: 06/13/2019
About: The purpose of this Funding Opportunity Announcement (FOA) is to support observational or intervention research focused on reducing health disparities in tobacco use in the United States. Specifically, this FOA is intended to stimulate scientific inquiry focused on innovative tobacco control policies.
Period of Support: Up to 2 years
Funds/Direct Costs: $275,000 direct costs for entire period of support
Program Contact: Bob Vollinger
(240) 276-6919
bob.vollinger@nih.gov

Multiple Institutes, including the National Cancer Institute
End-of-Life and Palliative Care Approaches to Advanced Signs and Symptoms (R21)
Deadline: 06/16/2019
About: The purpose of this funding opportunity announcement (FOA) is to stimulate research to examine the multi-dimensional foundations, experiences and management of complex, advanced signs and symptoms at the end of life.
Period of Support: Up to 2 years
Funds/Direct Costs: $275,000 direct costs for entire period of support
Program Contact: Karen Kehl
(301) 594-8010
kehlka@nih.gov

Multiple Institutes, including the National Cancer Institute
Harnessing Big Data to Halt HIV (R01 Clinical Trial Optional)
Deadline: 06/05/2019
About: The purpose of this Funding Opportunity Announcement (FOA) is to promote research that transforms understanding of HIV transmission, the HIV care continuum, and HIV comorbidities using Big Data Science (BDS). This FOA will support projects to assemble diverse big data sources, conduct robust and reproducible analyses, and create meaningful visualizations of big data, as well as, engage ethical experts where appropriate to ensure the development of this scientific area is guided by ethical principles.
Period of Support: Up to 5 years
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Program Contact: Geraldina Dominguez
(301) 496-3204
domingug@mail.nih.gov

National Cancer Institute
Innovative Approaches to Studying Cancer Communication in the New Media Environment (R21)
Deadline: 06/13/2019
About: This Funding Opportunity Announcement (FOA) invites applications that seek to apply one or more innovative methodologies in communication research across the cancer control continuum, from prevention, early detection, diagnosis, treatment, and survivorship, to end of life.
Period of Support: Up to 2 years
Funds/Direct Costs: $275,000 direct costs for entire period of support
Program Contact: Kelly Blake
(240) 281-5934
kelly.blake@nih.gov

Multiple Institutes, including the National Cancer Institute
Intervention Research to Improve Native American Health (R01)
Deadline: 05/14/2019
About: The purpose of this funding opportunity announcement (FOA) is to encourage exploratory developmental research to improve Native American (NA) health. Such research can include: conducting secondary analysis of existing data; merge various sources of data to answer critical research questions; conduct pilot and feasibility studies; and/or assess and validate measures that are being developed and/or adapted for use in NA communities.
Period of Support: Up to 5 years
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Program Contact: Shobha Srinivasan
(240) 276-6938
ss688k@nih.gov

Multiple Institutes, including the National Cancer Institute
Mechanisms Underlying the Contribution of Sleep Disturbances to Pain (R01 Clinical Trial Optional)
Deadline: 06/05/2019
About: The purpose of this Funding Opportunity Announcement (FOA) is to promote research that transforms understanding of sleep disturbances and pain. This FOA will support projects to assemble diverse data sources, conduct robust and reproducible analyses, and create meaningful visualizations of big data, as well as, engage ethical experts where appropriate to ensure the development of this scientific area is guided by ethical principles.
About: The purpose of this FOA is to encourage mechanistic research to investigate the impact of sleep disturbances on pain. The mechanisms and processes underlying the contribution of sleep and sleep disturbances to pain perception and the development and maintenance of chronic pain may be very broad. This FOA encourages interdisciplinary research collaborations by experts from multiple fields—neuroscientists, psychologists, endocrinologists, immunologists, geneticists, pharmacologists, chemists, physicists, behavioral scientists, clinicians, caregivers, and others in relevant fields of inquiry. Applications proposing to study the impact of pain on sleep will be considered low priority and are unlikely to be funded under this FOA.

Period of Support: Up to 5 years
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Program Contact: Diane St. Germain
(240) 276-7050
omaraa@mail.nih.gov

National Cancer Institute
Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21)
Deadline: 05/28/2019
About: This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology.

Period of Support: Up to 3 years
Funds/Direct Costs: Direct costs are limited to $400,000 over a 3-year period, with no more than $200,000 in direct costs allowed in any single year.
Program Contact: Tony Dickherber
(301) 547-9980
dickherberaj@mail.nih.gov

Request for Applications (RFA)

National Cancer Institute
Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33)
Deadline: 05/28/2019
About: This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research.

Period of Support: Up to 3 years
Funds/Direct Costs: Direct costs are limited to $300,000 per year.
Program Contact: Tony Dickherber
(301) 547-9980
dickherberaj@mail.nih.gov

National Cancer Institute
Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21)
Deadline: 05/28/2019
About: This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens.

Period of Support: Up to 3 years
Funds/Direct Costs: Direct costs are limited to $400,000 over a 3-year period, with no more than $200,000 in direct costs allowed in any single year.
Program Contact: Tony Dickherber
(301) 547-9980
dickherberaj@mail.nih.gov

National Cancer Institute
Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33)
Deadline: 05/28/2019
About: This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens.

Period of Support: Up to 3 years
**Funds/Direct Costs:** Direct costs are limited to $300,000 per year.

**Program Contact:** Tony Dickherber  
(301) 547-9980  
dickherberaj@mail.nih.gov

---

**Multiple Institutes, including the National Cancer Institute HEAL Initiative: Translational Development of Devices to Treat Pain (U18 Clinical Trial Not Allowed)**

**Deadline:** 06/20/2019  

**About:** The purpose of this Funding Opportunity Announcement (FOA) is to support preclinical development and demonstration of safe, effective, and non-addictive device-based technologies and approaches to treat pain. The goal of the program is to demonstrate treatment using credible neural targets for device-based interventions and/or diagnostics for pain, building upon the latest mechanistic knowledge about the anatomy and physiology of central, spinal, and peripheral pathways involved in pain.

**Period of Support:** Up to 3 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project. Budgets should rarely exceed $500,000 direct cost per year.

**Program Contact:** Diane St. Germain  
(240) 276-7082  
dstgermain@mail.nih.gov

---

**NEW National Cancer Institute**

**The Experimental Therapeutics Clinical Trials Network (ETCTN) Pharmacokinetic Resource Laboratories (U24)**

**Deadline:** 5/22/2019  

**About:** The purpose of this Funding Opportunity Announcement (FOA) issued by The National Cancer Institute (NCI) is to create Pharmacokinetics Resource Laboratories (PK Laboratories) that will support the Experimental Therapeutics Clinical Trials Network (ETCTN). The PK Laboratories will be expected to organize specimen collection and subsequent analysis of pharmacokinetic endpoints, drug-drug interactions, cytochromes P450 (CYP) interactions, and food effects in ETCTN studies of NCI Investigational New Drug (IND) agents.

**Period of Support:** 6 Years

**Funds/Direct Costs:** Application budget requests are limited to $320,000 (direct costs) per year.

**Program Contact:** S. Percy Ivy  
(240) 276-6107  
ivyp@ctep.nci.nih.gov

---

**NEW National Cancer Institute**

**The Experimental Therapeutics Clinical Trials Network (UM1 Clinical Trial Required)**

**Deadline:** 5/22/2019  

**About:** The purpose of this Funding Opportunity Announcement (FOA) issued by The National Cancer Institute (NCI) is to continue support for the Experimental Therapeutics Clinical Trials Network (ETCTN) for the efficient and comprehensive conduct of early phase clinical trials of NCI Investigational New Drug (IND) agents. The ETCTN is designed to assure the availability of investigators and programs with expertise in early drug development and translational research for this purpose.

**Period of Support:** 6 Years

**Funds/Direct Costs:** Application budget requests are limited to $1,250,000 (direct costs) per year.

**Program Contact:** S. Percy Ivy  
(240) 276-6107  
ivyp@ctep.nci.nih.gov

---

**NEW National Cancer Institute**

**Optimizing the Management and Outcomes for Cancer Survivors Transitioning to Follow-up Care (R01 Clinical Trial Required)**

**Deadline:** 6/28/2019  

**About:** This FOA solicits applications for new Behavioral and Social Sciences Research (BSSR) predoctoral training programs that focus on innovative computational and/or data science analytic approaches and their incorporation into training for the future BSSR health research workforce. The vision of the Advanced Data Analytics for BSSR training program is to support the development of a cohort of specialized predoctoral candidates who will possess advanced competencies in data science analytics to apply to an increasingly complex landscape of behavioral and social health-related big data.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are not limited, but each institutional training program will be asked to appoint up to 5 trainees annually. Budgets need to reflect the actual needs of the proposed project.

**Program Contact:** Susan Perkins  
(240) 276-5630
About: This FOA solicits applications that develop and test models of care for adult survivors of cancer who are transitioning from active treatment to follow-up care. Through this FOA, the NCI intends to support multi-level interventions that enhance communication, collaboration, and coordination among oncology and non-oncology providers to improve cancer survivor outcomes. 

Period of Support: Up to 5 years
Funds/Direct Costs: Application budgets are limited to $500,000 direct costs per year
Program Contact: Michelle Mollica
(240) 276-7621
michelle.mollica@nih.gov

NEW
National Cancer Institute
Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)
Deadline: 06/11/2019
About: The purpose of this Funding Opportunity Announcement (FOA) is to invite exploratory/developmental research grant applications (R21) for the development of innovative methods and algorithms in biomedical computing, informatics, and data science addressing priority needs across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities.

Period of Support: Up to 2 years
Funds/Direct Costs: Direct costs are limited to $275,000 over a two year period. No more than $200,000 may be requested in a single year.
Program Contact: Juli Klemm
(301) 480-5778
juli.klemm@nih.gov

NEW
National Cancer Institute
Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)
Deadline: 06/11/2019
About: The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities.

Period of Support: Up to 5 years
Funds/Direct Costs: Direct costs are limited to $300,000 per year
Program Contact: Juli Klemm
(301) 480-5778
juli.klemm@nih.gov

NEW
National Cancer Institute
Feasibility and Planning Studies for Development of Specialized Programs of Research Excellence (SPOREs) to Investigate Cancer Health Disparities (P20 Clinical Trial Optional)
Deadline: 06/19/2019

About: This Funding Opportunity Announcement (FOA) invites applications for development of translational research programs that are focused upon investigating
cancer health disparities. The P20 grants will support feasibility and planning activities to build comprehensive cancer health disparities research programs. It is the expectation that the research programs developed by the P20 awards should be competitive with other applications for a full Specialized Programs of Research Excellence (SPORE), addressing cancer health disparities as a cross-cutting research theme.

**Period of Support:** Up to 3 years

**Funds/Direct Costs:** Applicants may request a maximum of $800,000 direct costs per year

**Program Contact:** Tiffany Wallace
(240) 276-5114
wallaceti@mail.nih.gov

---

**Intramural Funding Opportunities**

**Massey Cancer Center**

**Ancillary Studies to Advance Knowledge on Biological and/or Behavioral Factors Relevant to Cancer (ABBC Award)**

**Deadline:** 05/25/2019

**About:** The intent of the ABBC Award is (1) to support the addition of behavioral, social or economic endpoints to studies where the primary focus is on biological or clinical endpoints or (2) to support the addition of biological or clinical data endpoints to studies where the primary endpoints are on behavioral, social, or economic measures. The ABBC Award is also intended to encourage multidisciplinary and inter-programmatic collaborations among members of Massey's research programs, especially collaborations involving members of the Cancer Prevention and Control program.

**Period of Support:** 1 year

**Funds/Direct Costs:** $25,000 for entire period

**Internal Contact:** Morgan Hembarsky
(804) 828-3114
mhembarsky@vcu.edu